Your browser doesn't support javascript.
loading
Weight loss during neoadjuvant chemotherapy impacts perioperative outcomes in patients undergoing surgery for pancreatic cancer.
Doshi, Sahil; Abad, John; Wells, Amy; Chawla, Akhil.
Affiliation
  • Doshi S; Northwestern University Feinberg School of Medicine, Chicago, IL, USA.
  • Abad J; Northwestern University Feinberg School of Medicine, Chicago, IL, USA; Division of Surgical Oncology, Department of Surgery, Northwestern Medicine Regional Medical Group, Winfield, IL, USA.
  • Wells A; Northwestern University Feinberg School of Medicine, Chicago, IL, USA; Division of Surgical Oncology, Department of Surgery, Northwestern Medicine Regional Medical Group, Winfield, IL, USA.
  • Chawla A; Northwestern University Feinberg School of Medicine, Chicago, IL, USA; Division of Surgical Oncology, Department of Surgery, Northwestern Medicine Regional Medical Group, Winfield, IL, USA; Robert H. Lurie Comprehensive Cancer Center, Chicago, IL, USA. Electronic address: akhil.chawla@nm.org.
Pancreatology ; 23(8): 1020-1027, 2023 Dec.
Article in En | MEDLINE | ID: mdl-37926598
ABSTRACT

BACKGROUND:

While use of neoadjuvant chemotherapy (NAC) in pancreatic adenocarcinoma (PDAC) downstages cancers to be eligible for resection, weight loss during the neoadjuvant period due to cancer progression, gastric outlet obstruction, or neoadjuvant therapy itself is an area of concern. The goal of this study is to determine the effect of weight loss during NAC on perioperative outcomes of pancreatectomies.

METHODS:

The NSQIP database 2014-2019 was utilized to study patients who received NAC for PDAC and underwent significant weight loss, defined as at least 10 % body weight loss in the six months prior to surgery. Univariate and multivariate analyses were conducted using Fisher's Exact Test, Pearson's Chi-squared Test, and logistic regression.

RESULTS:

Of the 5590 PDAC patients who received NAC, 913 (16%) experienced significant weight loss. Patients who experienced significant weight loss were more likely to experience at least one complication compared to those who did not undergo weight loss (42.2% vs. 38.7%, p = 0.023). Those who had significant weight loss were more likely to undergo unplanned intubation postoperatively (3.8% vs 2.2 %, p = 0.004), have postoperative ventilator need >48 h (3.7% vs 1.8%, p < 0.001), have postoperative septic shock (3.9% vs 1.8 %, p < 0.001), and undergo reoperation (6.0% vs 4.3%, p = 0.027). However, there were no differences for pancreatic fistula (7.7% vs 9.3 %, p = 0.15), readmission rates (15% vs 15 %, p = 0.7), or 30-day mortality (1.5% vs 1.2%, p = 0.5). Utilizing logistic regression, BMI (OR 1.05, p = 0.032), significant weight loss (OR = 1.18, p = 0.025), sex (OR = 1.26 with female baseline, p < 0.001), history of COPD (OR = 1.39, p = 0.012), hypertensive medication use (OR = 1.18, p = 0.004), and pancreatic radiotherapy (OR = 1.16, p = 0.010) were independent preoperative predictors of a post-operative complication.

CONCLUSIONS:

Nutritional measures to stabilize weight during NAC should be considered to decrease post-pancreatectomy complications.
Subject(s)
Key words

Full text: 1 Database: MEDLINE Main subject: Pancreatic Neoplasms / Adenocarcinoma Limits: Female / Humans Language: En Year: 2023 Type: Article

Full text: 1 Database: MEDLINE Main subject: Pancreatic Neoplasms / Adenocarcinoma Limits: Female / Humans Language: En Year: 2023 Type: Article